Francis Y. Lee

12.2k total citations · 2 hit papers
103 papers, 7.4k citations indexed

About

Francis Y. Lee is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Francis Y. Lee has authored 103 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 40 papers in Hematology and 34 papers in Oncology. Recurrent topics in Francis Y. Lee's work include Chronic Myeloid Leukemia Treatments (39 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Eosinophilic Disorders and Syndromes (16 papers). Francis Y. Lee is often cited by papers focused on Chronic Myeloid Leukemia Treatments (39 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Eosinophilic Disorders and Syndromes (16 papers). Francis Y. Lee collaborates with scholars based in United States, South Korea and Germany. Francis Y. Lee's co-authors include Neil P. Shah, Charles L. Sawyers, Derek Norris, Ping Chen, Chris Tran, Brian Druker, Michael W. Deininger, Michael C. Heinrich, Thomas O’Hare and Richard Jove and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Francis Y. Lee

101 papers receiving 7.2k citations

Hit Papers

2 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

2004 1.4k citations Francis Y. Lee, Derek Norris et al. profile →
In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

2005 812 citations Thomas O’Hare, Denise K. Walters et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francis Y. Lee United States	39	3.5k	2.6k	2.4k	1.9k	1.7k	103	7.4k
Justus Duyster Germany	52	3.5k 1.0×	2.2k 0.8×	3.9k 1.7×	851 0.5×	2.4k 1.4×	261	9.0k
Wolf‐Karsten Hofmann Germany	42	2.6k 0.8×	1.9k 0.7×	2.9k 1.2×	682 0.4×	768 0.4×	251	6.7k
Tessa L. Holyoake United Kingdom	59	7.5k 2.2×	4.7k 1.8×	3.8k 1.6×	2.1k 1.1×	2.2k 1.3×	219	11.1k
Marilyn L. Slovak United States	46	6.9k 2.0×	2.3k 0.9×	4.4k 1.9×	543 0.3×	4.0k 2.3×	152	11.7k
Taira Maekawa Japan	45	1.3k 0.4×	921 0.4×	1.9k 0.8×	525 0.3×	1.5k 0.9×	224	5.6k
Giovanni Cazzaniga Italy	44	4.7k 1.3×	1.6k 0.6×	2.8k 1.2×	395 0.2×	1.2k 0.7×	211	8.4k
Giuseppe Visani Italy	45	4.0k 1.1×	2.0k 0.8×	2.2k 0.9×	462 0.2×	1.4k 0.8×	285	6.6k
Steffen Koschmieder Germany	37	2.4k 0.7×	1.7k 0.7×	2.8k 1.2×	729 0.4×	730 0.4×	222	5.2k
Ali G. Turhan France	37	2.0k 0.6×	1.4k 0.5×	1.5k 0.6×	509 0.3×	1.0k 0.6×	184	4.0k
Carmelo Carlo‐Stella Italy	40	2.4k 0.7×	3.4k 1.3×	2.4k 1.0×	314 0.2×	3.0k 1.8×	350	9.1k

Countries citing papers authored by Francis Y. Lee

Since Specialization

Citations

This map shows the geographic impact of Francis Y. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francis Y. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francis Y. Lee more than expected).

Fields of papers citing papers by Francis Y. Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francis Y. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francis Y. Lee. The network helps show where Francis Y. Lee may publish in the future.

Co-authorship network of co-authors of Francis Y. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Francis Y. Lee. A scholar is included among the top collaborators of Francis Y. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francis Y. Lee. Francis Y. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gan, Donghao, Yong Ran, Hong Pan, et al.. (2025). The Sirt1‐Piezo1 Axis Promotes Bone Formation and Repair in Mice. Advanced Science. 12(44). e10103–e10103.

Kim, Sang‐Hun, Taylor Adams, Sang Eun Lee, et al.. (2022). VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology. 69(1). 22–33. 7 indexed citations

Kwon, Hyuk‐Kwon, Kristin E. Yu, Kareme D. Alder, et al.. (2022). Concurrent targeting of glycolysis in bacteria and host cell inflammation in septic arthritis. EMBO Molecular Medicine. 14(12). e15284–e15284. 10 indexed citations

Kwon, Hyuk‐Kwon, Kristin E. Yu, Kareme D. Alder, et al.. (2021). Dual therapeutic targeting of intra-articular inflammation and intracellular bacteria enhances chondroprotection in septic arthritis. Science Advances. 7(26). 30 indexed citations

Back, Jungho, Minh Nam Nguyen, Lu Li, et al.. (2021). Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction. Bone Research. 9(1). 43–43. 14 indexed citations

Yu, Kristin E., Hyuk‐Kwon Kwon, Christopher M. Dussik, et al.. (2020). Enhancement of Impaired MRSA-Infected Fracture Healing by Combinatorial Antibiotics and Modulation of Sustained Inflammation. Journal of Bone and Mineral Research. 37(7). 1352–1365. 7 indexed citations

Morgan, Katherine M., Bruce S. Fischer, Francis Y. Lee, et al.. (2017). Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma. Molecular Cancer Therapeutics. 16(12). 2759–2769. 51 indexed citations

Fischer, Charla R., Maya Mikami, Saqib Nizami, et al.. (2017). Calreticulin inhibits inflammation‐induced osteoclastogenesis and bone resorption. Journal of Orthopaedic Research®. 35(12). 2658–2666. 15 indexed citations

Wong, Tai W., Francis Y. Lee, Stuart L. Emanuel, et al.. (2011). Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families. Clinical Cancer Research. 17(12). 4031–4041. 18 indexed citations

10.

Guerrouahen, Bella S., Christos Vaklavas, Jukka Kanerva, et al.. (2010). Dasatinib Inhibits the Growth of Molecularly Heterogeneous Myeloid Leukemias. Clinical Cancer Research. 16(4). 1149–1158. 39 indexed citations

11.

Huang, Fei, Ann Greer, Warren Hurlburt, et al.. (2008). The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors. Cancer Research. 69(1). 161–170. 137 indexed citations

12.

Woods, Nicholas T., Hirohito Yamaguchi, Francis Y. Lee, Kapil N. Bhalla, & Hong‐Gang Wang. (2007). Anoikis, Initiated by Mcl-1 Degradation and Bim Induction, Is Deregulated during Oncogenesis. Cancer Research. 67(22). 10744–10752. 87 indexed citations

13.

Song, Lanxi, Mark Morris, Tapan Bagui, et al.. (2006). Dasatinib (BMS-354825) Selectively Induces Apoptosis in Lung Cancer Cells Dependent on Epidermal Growth Factor Receptor Signaling for Survival. Cancer Research. 66(11). 5542–5548. 183 indexed citations

14.

Lesslie, Donald P., Nila U. Parikh, Ami N. Shah, et al.. (2006). Combined activity of dasatinib (BMS-354825) and oxaliplatin in an orthotopic model of metastatic colorectal carcinoma. Cancer Research. 66. 1114–1114. 4 indexed citations

15.

Kellar, Kristen A., Matthew V. Lorenzi, Dan You, et al.. (2006). Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics. Molecular Cancer Therapeutics. 5(6). 1571–1576. 5 indexed citations

16.

Wong, Tai W., Francis Y. Lee, Chiang Yu, et al.. (2006). Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling. Clinical Cancer Research. 12(20). 6186–6193. 65 indexed citations

17.

Lee, Francis Y., Louis J. Lombardo, Amy Camuso, et al.. (2005). BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Cancer Research. 65. 159–159. 38 indexed citations

18.

O’Hare, Thomas, Denise K. Walters, Eric P. Stoffregen, et al.. (2005). In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants. Cancer Research. 65(11). 4500–4505. 812 indexed citations breakdown →

19.

Haluska, Paul, Joan M. Carboni, David A. Loegering, et al.. (2005). BMS-554417, an inhibitor of the insulin-like growth factor I receptor and insulin receptor, inhibits proliferation and induces mitochondrial pathway-mediated apoptosis in cancer cell lines. Cancer Research. 65. 1191–1191. 2 indexed citations

20.

Lee, Francis Y., Louis J. Lombardo, R. M. Borzilleri, et al.. (2004). Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668. Cancer Research. 64. 921–921. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact